Axial Spondyloarthritis (axSpA) Treatment Market is segmented By Drug Class (TNF Inhibitors (Infliximab, Etanercept), IL-17 Inhibitors (Secukinumab, Ixekizumab), Other Cl ....
Market Size in USD
CAGR7.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.5% |
Market Concentration | High |
Major Players | AbbVie Inc., Novartis AG, Pfizer Inc., UCB Pharma, Eli Lilly and Company |
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031. Increased prevalence of axSpA and rising population are major drivers responsible for growth of this market. Additionally, development and launch of novel biologic therapies for axSpA treatment such as IL-23 and IL-17 inhibitors have boosted the market growth over the past years.